Transfemoral: Upcoming valves

Matthew C. Henn, Alan Zajarias, Hersh S. Maniar

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Transcatheter valve implantation via the transfemoral approach has steadily evolved over the past decade. With the publication of large, multicenter trials evaluating the first-generation devices, it is clear that transcatheter valve implantation is a safe and effective treatment for aortic valve disease. However, several shortcomings have been identified: high incidences of cerebrovascular accidents, vascular complications, rhythm disturbances, paravalvular regurgitation, and malposition. These shortcomings combined with expanding indications have stimulated many companies to produce new second-generation devices aimed at reducing or eliminating these deficiencies. In particular, some second-generation transfemoral devices have been designed to be delivered through sheaths as small as 14 French with the ability to be repositioned and retrieved. With new devices being produced at an exponential rate both in the United States and throughout the entire world, evaluating each new device through rigorous preclinical and clinical trials is essential. Once safety and efficacy are confirmed, indications are well established, and technology has sufficiently matured, large randomized trials will be necessary to compare each transcatheter device.

Original languageEnglish
Title of host publicationCatheter Based Valve and Aortic Surgery
PublisherSpringer New York
Number of pages16
ISBN (Electronic)9781493934324
ISBN (Print)9781493934300
StatePublished - Jan 1 2016


  • Aortic valve disease
  • Aortic valve replacement
  • Balloon-expandable valves
  • New technology
  • Second-generation valves
  • Self-expandable valves
  • TAVI
  • TAVR
  • Transfemoral
  • Upcoming valves


Dive into the research topics of 'Transfemoral: Upcoming valves'. Together they form a unique fingerprint.

Cite this